A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults

To evaluate the efficacy of Tapinarof cream, 1% in subjects with atopic dermatitis (AD).

Dermavant Sciences, Inc.
Principal Investigator(s)
Dr. Jonathan Silverberg MD, PHD, MPH
Request Information
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.